Cancer

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC) (ACT-MBC)

   Rochester, Minn., Mankato, Minn., Eau Claire, Wis., Albert Lea, Minn.

   Collection of blood to track serial circulating tumor cells (CTCs) in subjects with metastatic breast cancer (MBC). Study will also collect data from investigators are Mayo Clinic and the Mayo Clinic Health Systems to determine effectiveness of the proposed process.

2. A Study to Compare Optimal MRI Timing for Pre-surgical Planning to LINAC-based Therapy

   Rochester, Minn.

   The purpose of this research is to compare two different standard-of-care pre-surgical imaging methods. 

3. SULF1 and SULF2 Role in Cholangiocarcinoma

   Rochester, Minn.

   Cholangiocarcinoma (CCA) has key similarities with HCC, therefore, we hypothesize that Sulf1 and Sulf2 may also play roles in promotion of CCA progression.

4. Biorepository for Acute Leukemia Research

   Rochester, Minn.

   The purpose of this IRB protocol is to establish a specimen bank for research into acute leukemias. In particular, we plan to bank blood and bone marrow from patients with newly diagnoses or relapsed acute leukemia (AML or ALL) for future biological studies. By accruing samples both at initial diagnosis and at relapse, we will be able to investigate not only the biology of these marrow disorders, but also the changes that occur to render these disorders resistant to therapy. These activities are a first step toward identifying alternative therapies and subsequently beginning to personalize the therapy for these disorders.

5. Patient Experience and Understanding of Genetic Testing in Ovarian Cancer

   Rochester, Minn.

   The purpose of this study is to investigate the experience and understanding of patients with ovarian cancer in relation to genetic testing by means of one-on-one qualitative interviews and survey.

6. YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) of YH001 when given with envafolimab dosed at 600 mg SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety and tolerability and determine RP2D of YH001 in combination with envafolimab dosed at 600 mg SC every 3 weeks and doxorubicin dosed at 75 mg/m2 every three weeks in patients with advanced or metastatic sarcoma who have not received doxorubicin or checkpoint inhibitors and are refractory to or intolerant to other available therapies.

7. Study of Validated Biomarkers in Urine for Patients with Adenocarcinoma of the Prostate

   Rochester, Minn.

   The purpose of this study is to assess the accuracy of DNA marker candidates (individually and in combination) assayed from urine and prostatic fluid (collected following digital prostate massage) for detection of prostate cancer.

8. A Study to Evaluate the Use of Organoids to Advance Precision Medicine in Bladder Cancer

   Rochester, Minn.

   The purpose of this study is to develop patient-derived organoid cultures of urothelial carcinoma from non-invasively obtained urine samples and to characterize the histological, molecular and functional features of patient-derived organoids.

9. Predicting Immunotherapy Response in Metastatic Kidney Cancer

   Rochester, Minn.

   Immunotherapy has revolutionized the therapeutic landscape for patients with metastatic RCC and response rates are higher than previously observed with tyrosine kinase inhibitors. Despite this, there is a growing need for molecular markers that can help identify patients who will benefit from immunotherapy, especially in the landscape of multiple available regimens, potential toxicities and financial burden. In this study, we propose to use blood biopsies to study tumor-derived extracellular vesicles (tdEVs) to assess disease burden, monitor response to therapy, and to predict earlier disease progression. In addition to tdEVs, these samples will also be analyzed for other biomarkers (circulating immune cells) to assess if they can be used to inform on tumor-immune cell interactions in real-time and potentially identify responders to immunotherapy.

10. Monoclonal Proteins by Blood Spot and Saliva

    Rochester, Minn.

    The purpose of this study is to assess the feasibility and develop procedures for detecting monoclonal proteins via finger pick blood spots and saliva. Data will be compared to results of serum data collected for patient care during the same time.  The test will be evaluated qualitatively against venipunctured data tested by Mass Fix.